Web Images Videos Maps News Shopping Gmail more »
Sign in
Scholar Home  
  Advanced Scholar Search
Scholar Preferences
Scholar Results 1 - 10 of about 101 related to van Wijk: Rosiglitazone improves postprandial triglyceride and free fatty acid metabolism.... (0.12 sec) 

Rosiglitazone improves postprandial triglyceride and free fatty acid metabolism in …

- diabetesjournals.org
JPH van Wijk, EJP de Koning, M Castro Cabezas, … - Diabetes Care, 2005 - Am Diabetes Assoc
RESULTS—Rosiglitazone did not change fasting plasma triglycerides compared with placebo
(1.97 ± 0.22 vs. 1.88 ± 0.20 mmol/l, respectively) but decreased postprandial triglyceride
levels, leading to significantly lower triglyceride dAUC (−37%, P < 0.05), without changing ...
Cited by 63 - Related articles - All 7 versions

The effects of rosiglitazone on fatty acid and triglyceride metabolism in type 2 …


GD Tan, BA Fielding, JM Currie, SM Humphreys, M … - Diabetologia, 2005 - Springer
Abstract Aims/hypothesis: We investigated the effects of rosiglitazone on NEFA and triglyceride
metabolism in type 2 diabetes. Methods: In a double-blind, placebo-con- trolled, cross-over study
of rosiglitazone in diet-treated type 2 diabetic subjects, we measured arteriovenous dif- ...
Cited by 85 - Related articles - All 2 versions

The effect of sensitisation to insulin with pioglitazone on fasting and postprandial …


KA Majali, MB Cooper, B Staels, G Luc, MR Taskinen, … - Diabetologia, 2006 - Springer
Abstract Aims/hypothesis: Insulin resistance is thought to be central to the pathogenesis of diabetic
dyslipidaemia. We hypothesised that improving insulin sensitivity would improve fasting and
postprandial triglyceride metabolism in patients with type 2 diabetes. To this aim we ...
Cited by 36 - Related articles - BL Direct - All 3 versions

Lack of effect of pioglitazone on postprandial triglyceride levels in type 2 diabetes

- diabetesjournals.org [PDF] 
D Shimono, N Kuwamura, Y Nakamura, H … - Diabetes Care, 2001 - Am Diabetes Assoc
In the Presidential Address in June of 1998 (1), I proudly announced that the recently adopted
Five Year Plan of the American Diabetes Association (ADA) contained the goal of allocating
one of ev- ery three dollars of total public support to research awards and grants by the ...
Cited by 8 - Related articles - BL Direct - All 4 versions

Effects of the PPARγ agonist pioglitazone on lipoprotein metabolism in patients …

- nih.gov
K Nagashima, C Lopez, D Donovan, C … - Journal of Clinical …, 2005 - Am Soc Clin Investig
Elevated plasma levels of VLDL triglycerides (TGs) are characteristic of patients with type 2 diabetes
mellitus (T2DM) and are associated with increased production rates (PRs) of VLDL TGs and
apoB. Lipoprotein lipase–mediated (LPL-mediated) lipolysis of VLDL TGs may also be ...
Cited by 89 - Related articles - All 8 versions

Peroxisome proliferator–activated receptor-γ agonist rosiglitazone reduces clinical …


G Wang, J Wei, Y Guan, N Jin, J Mao, X Wang - Metabolism, 2005 - Elsevier
Rosiglitazone, an agonist of peroxisome proliferator–activated receptor-γ (PPARγ), is an
insulin-sensitizing antidiabetic agent and inhibits restenosis in animal blood vessels.
However, its benefit for patients with type 2 diabetes and coronary artery disease (CAD) ...
Cited by 44 - Related articles - All 8 versions

Differential effect of pioglitazone (PGZ) and rosiglitazone (RGZ) on postprandial …


B Chappuis, M Braun, C Stettler, S Allemann, … - Diabetes/Metabolism … - interscience.wiley.com
It is also possible that your web browser is not configured or not able to display style sheets.
In this case, although the visual presentation will be degraded, the site should continue to be
functional. We recommend using the latest version of Microsoft or Mozilla web browser to ...
Cited by 18 - Related articles - BL Direct - All 4 versions

Impact of thiazolidenediones on serum lipoprotein levels


RB Goldberg - Current atherosclerosis reports, 2006 - Springer
The thiazolidinediones, acting through peroxisome proliferator–activated receptor γ (PPAR γ
), affect mul- tiple areas of metabolism. Of increasing importance is the recognition that these
agents affect lipoprotein metabolism and cause changes in serum lipid and lipo- protein ...
Cited by 18 - Related articles - BL Direct - All 3 versions

Effects of rosiglitazone on lipids, adipokines, and inflammatory markers in …


FF Samaha, PO Szapary, N Iqbal, MM … - … , and Vascular Biology, 2006 - Am Heart Assoc
Methods and Results— We performed a prospective, double-blinded, placebo-controlled study
of 60 nondiabetic subjects with low high-density lipoprotein cholesterol (HDL-C) level and metabolic
syndrome to rosiglitazone 8 mg daily or placebo for 12 weeks. We found no significant ...
Cited by 90 - Related articles - All 9 versions

Effects of nateglinide and glibenclamide on postprandial lipid and glucose …


J Vakkilainen, N Mero, A Schweizer, JE Foley, … - Diabetes/Metabolism … - interscience.wiley.com
It is also possible that your web browser is not configured or not able to display style sheets.
In this case, although the visual presentation will be degraded, the site should continue to be
functional. We recommend using the latest version of Microsoft or Mozilla web browser to ...
Cited by 34 - Related articles - BL Direct - All 5 versions


Result Page: 

1

2

3

4

5

6

7

8

9

10

Next


 


Go to Google Home - About Google - About Google Scholar

©2009 Google